Dana-Farber Cancer Institute
Latest From Dana-Farber Cancer Institute
October was an active fundraising month for both start-up biopharma companies and more established privately held firms, ranging from $3m for Appili's drug for anaerobic infections to $270m for Harmony's rare disease programs.
Emerging Company Profile: Former Sanofi-Genzyme exec David Meeker signed on to lead the startup, which is using a CRISPR-based drug discovery platform to develop specifically targeted therapies, with an initial focus on oncology and immunology, after leaving big pharma.
The rapidly accelerating complexity of oncology drug development demands a new way of doing business. To succeed in this new landscape, biopharma companies must transform their portfolios and partnerships, and shift toward more dynamic business and operating models and decision-making processes.
As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.